AstraZeneca weighs spinning out COVID-19 products into separate company: Bloomberg

AstraZeneca recently bundled its COVID-19 vaccine and antibody treatment into a separate division. But there’s a chance that the new unit might not stay with it for long.

The British drugmaker is considering the potential listing of the newly created vaccines and immune therapies division into a separate entity as part of a review of the best path forward, Bloomberg reported, citing people with knowledge of the discussions.